NCT06362096View on ClinicalTrials.gov

A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab+pyrotinib+taxene

Trastuzumab (first cycle 8mg/Kg, subsequent 6mg/Kg, iv, q3w) Pyrrotinib \* po, qd, q3w The first cycle 240mg+ montmorillonite powder, the second cycle 320mg+ montmorillonite powder prevention Subsequent cycle 400mg+\* montmorillonite powder used when necessary taxenes

All Listed Sponsors
lead

Huihua Xiong

OTHER

NCT06362096 - A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer | Biotech Hunter | Biotech Hunter